Latest Pharmaceuticals News

Page 9 of 89
Dimerix has secured Mexican composition of matter protection for its Phase 2-ready kidney drug DMX-652 until June 2041. The grant expands the asset’s patent estate ahead of planned clinical testing in acute kidney injury, although it brings no new clinical data or regulatory approval.
Victor Sage
Victor Sage
14 Sept 2026
Telix’s Pixclara has become the first FDA-approved FET-PET imaging drug for glioma, opening a new US diagnostic pathway for adults and children. The approval is commercially significant, but pricing, reimbursement and launch timing remain undisclosed.
Victor Sage
Victor Sage
14 Sept 2026
A multimillion-dollar, multiyear NIH grant will fund an expanded access program for Neurizon’s investigational NUZ-001, potentially giving up to 200 US patients access to the therapy for as long as 96 weeks. The program is designed to add long-term safety, survival and biomarker data alongside the pivotal HEALEY ALS trial.
Ada Torres
Ada Torres
9 Sept 2026
Clever Culture Systems secures a follow-up order from Novo Nordisk for two APAS Independence instruments, marking a critical step toward broader global deployment and signalling expected sales growth from FY27.
Ada Torres
Ada Torres
7 Sept 2026
Neurizon has appointed Dr Chris Bremer as chief executive as its NUZ-001 ALS program moves towards topline Phase 2/3 results expected in late Q2 2027. The incoming CEO brings more than 20 years of pharmaceutical and biotechnology experience, including over US$1 billion in licensing transactions.
Ada Torres
Ada Torres
7 Sept 2026
Telix Pharmaceuticals has completed enrollment in its pivotal Phase 3 BiPASS trial for prostate cancer imaging and aligned with the FDA on a pathway that could expand U.S. patient access and reimbursement for its 68Ga-PSMA-PET agents.
Ada Torres
Ada Torres
2 Sept 2026
Recce Pharmaceuticals narrowed its operating loss to AUD 15 million in FY26, progressing Phase 3 trials for its anti-infective RECCE 327 and securing key patents and commercial partnerships.
Ada Torres
Ada Torres
31 Aug 2026
Advance ZincTek posted an 11% rise in FY26 profit before tax to $2.247 million on 12.6% higher sales, driven by AI integration and US market strength. The company is set to enter residential battery manufacturing in FY27, leveraging its zinc oxide expertise.
Maxwell Dee
Maxwell Dee
31 Aug 2026
BLS Pharmaceuticals (ASX: BLS) reported a standout FY26 with revenue surging 161% to $74.2 million and net profit more than tripling to $15.4 million, driven by expanded manufacturing and major international contracts including a $50 million German supply deal.
Victor Sage
Victor Sage
31 Aug 2026
Clever Culture Systems expanded its pharmaceutical customer base to eight in FY26, placing 11 APAS Independence instruments and completing its product offering with a contact plate module. Despite a $2.24 million net loss, the company expects meaningful sales growth in FY27 backed by a robust pipeline and disciplined financial management.
Victor Sage
Victor Sage
31 Aug 2026
Avecho has resumed enrolment for the last stage of its pivotal Phase III trial of a TPM®-enhanced CBD capsule for insomnia, following a unanimous Data Monitoring Board recommendation to continue without expanding the sample size.
Ada Torres
Ada Torres
31 Aug 2026
Island Pharmaceuticals has obtained regulatory rights to reference critical Marburg-Angola virus natural history data, clearing a significant FDA hurdle for its antiviral Galidesivir. This milestone accelerates the path toward pivotal animal studies and potential FDA approval under the Animal Rule.
Victor Sage
Victor Sage
31 Aug 2026

Browse the archive

Full archive